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Background: Eosinophilic granulomatosis with polyangiitis (EGPA) belongs to the systemic ANCA-associated
vasculitides which may develop life-threatening major organ involvement, such as eosinophilic pulmonary
infiltration, neuropathy, acute nephritis, myocarditis, and gastrointestinal (GI) tract involvement. Here, two cases of
EGPA are presented developing perforation of the bowel at primary diagnosis after 7 respectively 10 days of
initiation of high-dose glucocorticosteroides (GC) therapy.
Findings: Two male patients, aged 32 (case 1) and 36 years (case 2), were admitted to the hospital with the
symptoms of dyspnea, fatigue, fever, and chest pain. The patients completed the previously published revised
international Chapel Hill nomenclature of EGPA. The two patients (case 1 and 2) developed acute abdominal pain
after 7 (case 1) and ten days (case 2) on GC treatment. Computed tomography followed by surgery detected acute
perforation of the small intestine (middle part of jejunum, case 1) and colon transversum (case 2). The resected
specimens disclosed bowel perforation with severe transmural inflammation, edema, hemorrhage and vasculitis
typically of EGPA. On the first post-operative day, therapy with cyclophosphamide (according to the Austin
protocol) with a dosage of 750 mg/qm every 3 weeks (for 8 cycles) was initiated with good response within three
months of treatment.
Conclusion: The course of disease of the two presented EGPA patients suggest that very early initiation of
intensified immunosuppressive treatment, preferentially with cyclophophomide or B cell depletion strategies, needs
to be considered to avoid life-threatening complications of GI involvement.
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PerforationIntroduction
Eosinophilic granulomatosis with polyangiitis (EGPA)
belongs to the systemic vasculitides which may develop
life-threatening major organ involvement Any type of vas-
culitis has the potential to cause local or diffuse patho-
logical changes in the gastrointestinal (GI) tract based on
the inflammation of vessel walls, followed by alterations of
the blood flow and ischemic damage to the dependent* Correspondence: gunter.assmann@uks.eu
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in any medium, provided the original work is porgan (Çileda» et al. 2012; Singh et al. 2009; Venditti et al.
2011). Intestinal manifestations have to be considered
more common in other vasculitis disease, such as polyar-
teriitis nodosa, however, it seems to occur as severe mani-
festation of EGPA (Nakamura et al. 2002). Several case
reports have been published with EGPA and GI tract in-
volvement. Venditti et al. have previously published a case
of EGPA vasculopathy with large bowel perforation, how-
ever, the patient has been under long-term treatment of
GC during his course of disease (Venditti et al. 2011).
Two cases of EGPA have been presented with intestinal
vasculitis, one of them with perforation as initialis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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hospital (Venditti et al. 2011; Murakami et al. 2004).
Varbanova et al. have presented a similar EGPA case to
the cases, which here have been presented, showing vascu-
litic intestine perforation within 3 weeks after diagnosis of
EGPA (Varbanova et al. 2011). Guellivin et al. have pub-
lished data from a relatively large cohort of 96 patients:
during the course of EGPA 30% of patients develop GI
symptoms, such as abdominal pain, melena or hematem-
esis indicating intestinal vasulitic involvement (Guillevin
et al. 1999). These data correspond to results from another
cohort consisting in 150 EGPA patients previously pub-
lished by (Moosig et al. 2013).
Here, two cases of EGPA are presented developing per-
foration of the bowel after initiation of high-dose GC
therapy.
Patients and methods
The study was performed in compliance with the
Helsinki Declaration, all patients have given the in-
formed written consent to take part in the study, the
agreement to perform the study was given by the Ethic
Committee Saarland.
Two male patients, aged 32 (case 1) and 36 years (case
2), were admitted to the hospital with the symptoms of
dyspnea, fatigue, fever, and chest pain (Table 1). Following
diagnostic procedures, the patients complied with the pre-
viously published revised international Chapel Hill nomen-
clature of EGPA (Jennette et al. 2013), showing major
organ involvement: myocarditis with heart failure NYHA
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aintraveneous application once a day; bGC = glucocorticosteroides, till perforation fo
polyangiitis; chistological proved by myocardial biopsy; dcounted in periphereal blo
autoantibodies, tested by immunofluorescence test and by ELISA for myeloperoxida
classification of heart failure.(only case 2), bronchial asthma with eosinophile infiltra-
tions, mild proteinuria (only case 1), and glomerular
hematuria (only case 2). After bronchoalveolar lavage and
biopsy of the skin (only case 1), treatment with GC at a
dose of 1 mg per kg/body weight was started. During GC
administration the major organ manifestations were evalu-
ated by completing diagnostic procedures, including biopsy
of the suralis nerve (only case 1), endoscopy with multiple
biopsies of the upper and lower intestine, MRI of the heart,
and renal biopsy (only case 2).
Results
The two patients (case 1 and 2) developed acute abdom-
inal pain after 7 (case 1) and ten days (case 2) on GC
treatment and three and five days, respectively, after en-
doscopy. The performed biopsies during the endoscopy
demonstrated vasculitis spots in both patients, but only
in the upper intestine. Computed tomography followed
by surgery detected an acute perforation of the small in-
testine (middle part of jejunum, case 1) and colon trans-
versum (case 2). The resected specimen disclosed bowel
perforation with severe transmural inflammation, edema,
hemorrhage and vasculitis typical of EGPA. Figure 1
shows the endoscopic (figure A) and macroscopic view
(figure B) of the resection specimen with multiple vascu-
litis induced necrotizing lesions with the corresponding
histological preparation (figure C) after surgery (case 2).
The colon perforation in case two was shown not to
have occurred due to previously performed endoscopy
biopsies. On the first post-operative day, therapy with
cyclophosphamide due to major organ involvements’ characteristics (case 1, 2)
Patient 1 Patient 2
4/2010 1/2009




Mononeuritis multiplex L1 Polyneuropathy
Bronchial asthma Asthma bronchiale
Eosophile infiltration
Mild proteinuria (0.5 g/24 h) Glomerular hematuria
5500/μl 4900/μl
Elevated Elevated
12.8 U/mlf 14.1 U/mlf
llowed by abdominal surgery; EGPA = eosinophilic granulomatosis with
od; epANCA = perinuclear pattern of antineutrophilic cytoplasmatic
se autoantibodies (anti-MPO) fin U/ml; NYHA = New York Heart Association
Figure 1 Colon transversum perforation of Churg Strauss patient (case 2) due to vasculitis. A: EGPA in case 2 and endoscopy in transverse
colon with vasculitis lesions. B: EGPA in case 2 and macroscopic view of the resected transverse colon with vasculitis necrotizing lesions after surgery.
C: EGPA in case 2 and histologic preparation of the resected transvere colon with eosinophilic infiltration and thrombotic vessel occlusion.
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750 mg/qm every 3 weeks (for 8 cycles) was initiated
with good response within three months of treatment
(case 1 and 2). Until the sixth month, the patients re-
ceived azathioprine 2.5 mg/kg body weight without re-
lapse of disease, and a reduction to a dose of 7.5 mg
prednisolone per day was implemented.
The good response of treatment was documented in re-
duction of eoasinophilic granulocytes lower than 2000/μl,
normalization of the lung spirometry, complete remis-
sion of the myocarditis (measeared with MRI), and
normalization of kidney function (with normal urine
sediment test). However, both of them showed not ame-
liorated but persistent neuropathy, and patient one suf-
fered from a persistent reduced ejection fraction of the
heart after 12 weeks. The p-ANCA levels have not
changed during the treatment period in both cases.
Discussion
We present two cases of GI perforation within two weeks
after primary diagnosis of EGPA under treatment of high-
dose GC. The macroscopic and histologic preparation of
the involved intestinal tract proved unconstrained inflam-
mation as the most probable cause of perforation. After
immediate postoperative initiation of intravenous cyclo-
phosphamide treatment both cases have shown clinical re-
mission during the following 12 weeks.
The treatment of EGPA with GI vasculitic involve-
ment at primary diagnosis may not be sufficiently
treated by GC alone to protect from life-threatening
and very early occuring complications such as GI per-
foration. Murakami et al. has published a similar case of
primary diagnosis of EGPA with GI perforation 20 days
after admission to hospital, however, the GC dosage was
lower (Murakami et al. 2004).
In general, GI involvement seems to be an indicator of
poor prognosis in this disease entity and has been re-
ported in an estimated 20 – 50% of patients (Guillevin
et al. 1996; Hayami et al. 2012; Bourgarit et al. 2005).
However, larger, more informative clinical study cohorts
of EGPA patients to evaluate the true prognostic impact
of GI vasculitis are currently not available. Nevertheless,previously published data from the French Vasculitis
Study Group have evaluated the “five factors score” (FFS)
to predict the risk of death due to EGPA (Bourgarit et al.
2005); the FFS score is widely used to assess the EGPA
prognosis by giving one point for the involvement of GI,
one point for involvement of the heart and the central
nervous system, respectively, and one or two for the kid-
ney manifestation (depending on serum creatinine and
proteinuria) (Pagnoux et al. 2007; Guillevin et al. 2011;
Vaglio et al. 2012). In general, Moosig et al. has demon-
strated the probable benefit of immunosuppressive treat-
ment beyond GC in all stages of EGPA patients out of
the Northern German vasculitis centre cohort (Moosig
et al. 2013); in detail, with an initial FFS (score) of one
or higher, the intravenous bolus application of cyclo-
phosphamide has been documented as the most fre-
quent treatment regime (71%).
In synopsis with the two cases we have presented here,
there appears to be a rationale for an intensified im-
munosuppressive treatment approach beyond GC within
the first week after EGPA diagnosis with GI involvement;
conventional therapies such as cyclophosphasmide or
previously establishing biological treatment modalities
such as B cell depletion needs to be considered to avoid
life-threatening GI manifestations with the goal to im-
prove the outcome.
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